End-Stage Coronary Artery Disease Market

DelveInsight's "End-Stage Coronary Artery Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the End-Stage Coronary Artery Disease, historical and forecasted epidemiology as well as the End-Stage Coronary Artery Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The End-Stage Coronary Artery Disease market report provides current treatment practices, emerging drugs, End-Stage Coronary Artery Disease market share of the individual therapies, current and forecasted End-Stage Coronary Artery Disease market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current End-Stage Coronary Artery Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the End-Stage Coronary Artery Disease market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

End-Stage Coronary Artery Disease Disease Understanding and Treatment Algorithm

The DelveInsight’s End-Stage Coronary Artery Disease market report gives a thorough understanding of the End-Stage Coronary Artery Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

End-Stage Coronary Artery Disease Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for End-Stage Coronary Artery Disease.

End-Stage Coronary Artery Disease Treatment

It covers the details of conventional and current medical therapies available in the End-Stage Coronary Artery Disease market for the treatment of the condition. It also provides End-Stage Coronary Artery Disease treatment algorithms and guidelines in the United States, Europe, and Japan.

End-Stage Coronary Artery Disease Epidemiology 

The End-Stage Coronary Artery Disease epidemiology section provides insights about the historical and current End-Stage Coronary Artery Disease patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the End-Stage Coronary Artery Disease market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted End-Stage Coronary Artery Disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- End-Stage Coronary Artery Disease Epidemiology

The epidemiology segment also provides the End-Stage Coronary Artery Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

End-Stage Coronary Artery Disease Recent Developments

• In March 2025, Caristo Diagnostics announced it received FDA 510(k) clearance for its CaRi-Plaque™ technology, an AI-assisted image analysis application designed to aid in the diagnosis of coronary artery disease (CAD).
• In March 2025, the FDA approved the first generics of Xarelto (rivaroxaban) 2.5 mg tablets, an anticoagulant to prevent deep vein thrombosis in adults with peripheral artery disease and to reduce the risk of major cardiovascular events in adults with coronary artery disease.
• In Feb 2025, Artrya Limited submitted its response to the FDA’s queries regarding its 510(k) application for the Salix® Coronary Anatomy product. The company expects regulatory clearance by the end of March 2025, marking a key milestone in offering its AI-based coronary disease detection technology in the US market.
• In February 2025, Riverain Technologies announced its expansion into eight countries in 2024, adding nearly 50 new customers with its ClearRead solutions to improve detection of cardiothoracic diseases. Building on 147% growth in 2024, the company is entering 2025 with new FDA-cleared technology that extends ClearRead CT functionality, offering coronary artery calcium (CAC) scores for ungated scans without contrast. This advancement enables opportunistic screening for coronary heart disease, the leading cause of death globally.
• On November 1, 2024, HeartLung Technologies, a Houston-based AI company, announced that it has received 510(k) clearance from the U.S. FDA for its new software, AutoChamber. This software assesses chest CT scans for indicators of coronary artery disease (CAD) and other serious heart conditions, focusing on opportunistic heart evaluations.
• On September 27, 2024, GE HealthCare announced FDA approval of FLYRCADO™ (flurpiridaz F 18), the first positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD). Flyrcado offers superior diagnostic efficacy compared to the widely used single-photon emission computed tomography (SPECT) MPI, enhancing access to PET MPI and improving accuracy, particularly in challenging cases like high BMI patients and women.

End-Stage Coronary Artery Disease Drug Chapters

The drug chapter segment of the End-Stage Coronary Artery Disease report encloses the detailed analysis of End-Stage Coronary Artery Disease marketed drugs and late-stage (Phase-III and Phase-II) End-Stage Coronary Artery Disease pipeline drugs. It also helps to understand the End-Stage Coronary Artery Disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

End-Stage Coronary Artery Disease Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for End-Stage Coronary Artery Disease treatment.

End-Stage Coronary Artery Disease Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for End-Stage Coronary Artery Disease treatment.

End-Stage Coronary Artery Disease Market Outlook

The End-Stage Coronary Artery Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted End-Stage Coronary Artery Disease market trends by analyzing the impact of current End-Stage Coronary Artery Disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of End-Stage Coronary Artery Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated End-Stage Coronary Artery Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the End-Stage Coronary Artery Disease market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the End-Stage Coronary Artery Disease market in 7MM.

The United States Market Outlook

This section provides the total End-Stage Coronary Artery Disease market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total End-Stage Coronary Artery Disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total End-Stage Coronary Artery Disease market size and market size by therapies in Japan is also mentioned.

End-Stage Coronary Artery Disease Drugs Uptake

This section focuses on the rate of uptake of the potential End-Stage Coronary Artery Disease drugs recently launched in the End-Stage Coronary Artery Disease market or expected to get launched in the market during the study period 2019-2032. The analysis covers End-Stage Coronary Artery Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.   

End-Stage Coronary Artery Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of End-Stage Coronary Artery Disease market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

End-Stage Coronary Artery Disease Pipeline Development Activities

The End-Stage Coronary Artery Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses End-Stage Coronary Artery Disease key players involved in developing targeted therapeutics.

Pipeline Development Activities

The End-Stage Coronary Artery Disease report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for End-Stage Coronary Artery Disease emerging therapies.

Reimbursement Scenario in End-Stage Coronary Artery Disease

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current End-Stage Coronary Artery Disease market trends, we take KOLs and SMEs ' opinion working in the End-Stage Coronary Artery Disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or End-Stage Coronary Artery Disease market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the End-Stage Coronary Artery Disease Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of End-Stage Coronary Artery Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the End-Stage Coronary Artery Disease epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for End-Stage Coronary Artery Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the End-Stage Coronary Artery Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global End-Stage Coronary Artery Disease market

Report Highlights

• In the coming years, the End-Stage Coronary Artery Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence End-Stage Coronary Artery Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for End-Stage Coronary Artery Disease. The launch of emerging therapies will significantly impact the End-Stage Coronary Artery Disease market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for End-Stage Coronary Artery Disease
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

End-Stage Coronary Artery Disease Report Insights

• End-Stage Coronary Artery Disease Patient Population
• Therapeutic Approaches
• End-Stage Coronary Artery Disease Pipeline Analysis
• End-Stage Coronary Artery Disease Market Size and Trends
• End-Stage Coronary Artery Disease Market Opportunities
• Impact of upcoming End-Stage Coronary Artery Disease Therapies

End-Stage Coronary Artery Disease Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• End-Stage Coronary Artery Disease Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

End-Stage Coronary Artery Disease Report Assessment

• Current Treatment Practices
• Unmet Needs
• End-Stage Coronary Artery Disease Pipeline Product Profiles
• End-Stage Coronary Artery Disease Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the End-Stage Coronary Artery Disease drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the End-Stage Coronary Artery Disease total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest End-Stage Coronary Artery Disease market size during the forecast period (2019-2032)?
• At what CAGR, the End-Stage Coronary Artery Disease market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the End-Stage Coronary Artery Disease market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the End-Stage Coronary Artery Disease market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the End-Stage Coronary Artery Disease?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical End-Stage Coronary Artery Disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of End-Stage Coronary Artery Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to End-Stage Coronary Artery Disease?
• Out of all 7MM countries, which country would have the highest prevalent population of End-Stage Coronary Artery Disease during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the End-Stage Coronary Artery Disease treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of End-Stage Coronary Artery Disease in the USA, Europe, and Japan?
• What are the End-Stage Coronary Artery Disease marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of End-Stage Coronary Artery Disease?
• How many therapies are in-development by each company for End-Stage Coronary Artery Disease treatment?
• How many are emerging therapies in mid-stage, and late stage of development for End-Stage Coronary Artery Disease treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the End-Stage Coronary Artery Disease therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for End-Stage Coronary Artery Disease and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for End-Stage Coronary Artery Disease?
• What are the global historical and forecasted market of End-Stage Coronary Artery Disease?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the End-Stage Coronary Artery Disease market
• To understand the future market competition in the End-Stage Coronary Artery Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for End-Stage Coronary Artery Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for End-Stage Coronary Artery Disease market
• To understand the future market competition in the End-Stage Coronary Artery Disease market